Nord/LB Analysts Give Merck KGaA (MRK) a €94.00 Price Target

Nord/LB set a €94.00 ($109.30) price target on Merck KGaA (FRA:MRK) in a report issued on Friday, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.

Other analysts have also recently issued research reports about the company. DZ Bank reiterated a neutral rating on shares of Merck KGaA in a research report on Tuesday, April 2nd. Sanford C. Bernstein set a €108.00 ($125.58) target price on Merck KGaA and gave the stock a neutral rating in a research report on Monday, April 15th. Barclays set a €82.00 ($95.35) target price on Merck KGaA and gave the stock a sell rating in a research report on Friday, May 3rd. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on Merck KGaA and gave the stock a neutral rating in a research report on Monday, May 13th. Finally, UBS Group set a €104.00 ($120.93) target price on Merck KGaA and gave the stock a neutral rating in a research report on Monday, May 13th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and five have issued a buy rating to the stock. Merck KGaA has a consensus rating of Hold and a consensus target price of €101.35 ($117.85).

MRK opened at €91.02 ($105.84) on Friday. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Read More: Trading Ex-Dividend

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.